Laboratory and clinical studies on norfloxacin in pediatrics

Sato Yoshitake, Iwata Satoshi, Akita Hironobu, Sunakawa Keisuke

研究成果: Article査読


Norfloxacin (NFLX, AM-715) is a new quinolone antibacterial agent. In the present study, we carried out laboratory and clinical investigations on NFLX in the field of pediatrics. The obtained results are summarized as follows. 1. NFLX was very active against Escherichia coli, Salmonella sp., Klebsiella sp., Entero- bacter sp. and Pseudomonas aeruginosa among Gram-negative rods. Antibacterial activities of NFLX against Gram-positive cocci were lower than those against Gram-negative rods but superior to activities of usual quinolone agents. MIC values of NFLX against Campylobacter jejuni were distributed in a range of :≤0.05~0.78µg/ml. 2. A peak serum level of 0.49 µg/ml was observed in 2 subjects and its urinary recoveries were 13.7%, 21.5%, respectively. 3. Clinical efficacies to NFLX were excellent in 25 patients and good in 9 patients with a efficacy rate of 92%. In a bacteriological examination, causative organisms were eradicated with an eradication rate of 87%. 4. No side effects were observed except eosinophillia in 1 patient. These findings indicate that NFLX will be useful and safe drug against bacterial infections in pediatrics.

ジャーナルthe japanese journal of antibiotics
出版ステータスPublished - 1990

ASJC Scopus subject areas

  • 微生物学(医療)
  • 薬理学(医学)
  • 感染症


「Laboratory and clinical studies on norfloxacin in pediatrics」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。